Treatment of HIV infection using protease inhibitors is frequently associated with lipodystrophy and impaired lipid and glucose metabolism. We examined the effect of saquinavir, one of the protease inhibitors, on lipid metabolism and glucose transport in cultured adipocytes. Saquinavir inhibited lipoprotein lipase (LPL) activity in 3T3-F442A and 3T3-L1 adipocytes. The inhibition of LPL was 81% at a concentration of 20 microg/ml. Another closely related drug, indinavir, had a small inhibitory effect. Saquinavir also inhibited the biosynthesis of lipids from [(14)C]-acetate. Saquinavir increased the lipolysis. Saquinavir had no significant effect on the cellular protein synthesis or protein content. Saquinavir increased the basal glucose transport threefold and decreased insulin-stimulated glucose transport by 35%. These studies suggest that some HIV protease inhibitors have direct effects on lipid and glucose metabolism. This inhibition of lipogenesis and glucose transport may explain some of the lipodystrophy, dyslipidemia and disturbed glucose metabolism with the clinical use of these drugs.

This article has been cited by other articles:

				M. J. Carper, W. T. Cade, M. Cam, S. Zhang, A. Shalev, K. E. Yarasheski, and S. Ramanadham HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E558 - E567. [Abstract] [Full Text] [PDF]

				R. V Sekhar, F. Jahoor, H. J Pownall, K. Rehman, J. Gaubatz, D. Iyer, and A. Balasubramanyam Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome Am. J. Clinical Nutrition, June 1, 2005; 81(6): 1405 - 1410. [Abstract] [Full Text] [PDF]

				D. C. Adler-Wailes, H. Liu, F. Ahmad, N. Feng, C. Londos, V. Manganiello, and J. A. Yanovski Effects of the Human Immunodeficiency Virus-Protease Inhibitor, Ritonavir, on Basal and Catecholamine-Stimulated Lipolysis J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3251 - 3261. [Abstract] [Full Text] [PDF]

				L. Q. Hong-Brown, C. R. Brown, and C. H. Lang Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1482 - C1492. [Abstract] [Full Text] [PDF]

				J. A. Johnson, J. B. Albu, E. S. Engelson, S. K. Fried, Y. Inada, G. Ionescu, and D. P. Kotler Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E261 - E271. [Abstract] [Full Text] [PDF]

				K. E. Yarasheski, P. Tebas, S. Claxton, D. Marin, T. Coleman, W. G. Powderly, and C. F. Semenkovich Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E899 - E905. [Abstract] [Full Text] [PDF]

				D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, K. E. Yarasheski, and S. Klein Alterations in lipid kinetics in men with HIV-dyslipidemia Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E490 - E497. [Abstract] [Full Text] [PDF]

				H. J. Woerle, P. R. Mariuz, C. Meyer, R. C. Reichman, E. M. Popa, J. M. Dostou, S. L. Welle, and J. E. Gerich Mechanisms for the Deterioration in Glucose Tolerance Associated With HIV Protease Inhibitor Regimens Diabetes, April 1, 2003; 52(4): 918 - 925. [Abstract] [Full Text] [PDF]

				C. Cammalleri and R. J. Germinario The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling J. Lipid Res., January 1, 2003; 44(1): 103 - 108. [Abstract] [Full Text] [PDF]

				D. Chen, A. Misra, and A. Garg Lipodystrophy in Human Immunodeficiency Virus-Infected Patients J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4845 - 4856. [Abstract] [Full Text] [PDF]